

Age and Association of Kidney Measures With Mortality and End-stage Renal Disease

Stein I. Hallan, MD, PhD
 Kunihiko Matsushita, MD, PhD
 Yingying Sang, MS
 Bakhtawar K. Mahmoodi, MD, PhD
 Corri Black, MBChB, MSc, FFPH
 Areef Ishani, MD, MS
 Nanne Kleefstra, MD, PhD
 David Naimark, MD, MSc, FRCP(C)
 Paul Roderick, MD, FRCP
 Marcello Tonelli, MD, SM
 Jack F. M. Wetzels, MD, PhD
 Brad C. Astor, PhD, MPH
 Ron T. Gansevoort, MD, PhD
 Adeera Levin, MD
 Chi-Pang Wen, MD, MPH, DrPH
 Josef Coresh, MD, PhD
 for the Chronic Kidney Disease
 Prognosis Consortium

Context Chronic kidney disease (CKD) is prevalent in older individuals, but the risk implications of low estimated glomerular filtration rate (eGFR) and high albuminuria across the full age range are controversial.

Objective To evaluate possible effect modification (interaction) by age of the association of eGFR and albuminuria with clinical risk, examining both relative and absolute risks.

Design, Setting, and Participants Individual-level meta-analysis including 2 051 244 participants from 33 general population or high-risk (of vascular disease) cohorts and 13 CKD cohorts from Asia, Australasia, Europe, and North/South America, conducted in 1972-2011 with a mean follow-up time of 5.8 years (range, 0-31 years).

Main Outcome Measures Hazard ratios (HRs) of mortality and end-stage renal disease (ESRD) according to eGFR and albuminuria were meta-analyzed across age categories after adjusting for sex, race, cardiovascular disease, diabetes, systolic blood pressure, cholesterol, body mass index, and smoking. Absolute risks were estimated using HRs and average incidence rates.

Results Mortality (112 325 deaths) and ESRD (8411 events) risks were higher at lower eGFR and higher albuminuria in every age category. In general and high-risk cohorts, relative mortality risk for reduced eGFR decreased with increasing age; eg, adjusted HRs at an eGFR of 45 mL/min/1.73 m² vs 80 mL/min/1.73 m² were 3.50 (95% CI, 2.55-4.81), 2.21 (95% CI, 2.02-2.41), 1.59 (95% CI, 1.42-1.77), and 1.35 (95% CI, 1.23-1.48) in age categories 18-54, 55-64, 65-74, and ≥75 years, respectively (*P* < .05 for age interaction). Absolute risk differences for the same comparisons were higher at older age (9.0 [95% CI, 6.0-12.8], 12.2 [95% CI, 10.3-14.3], 13.3 [95% CI, 9.0-18.6], and 27.2 [95% CI, 13.5-45.5] excess deaths per 1000 person-years, respectively). For increased albuminuria, reduction of relative risk with increasing age was less evident, while differences in absolute risk were higher in older age categories (7.5 [95% CI, 4.3-11.9], 12.2 [95% CI, 7.9-17.6], 22.7 [95% CI, 15.3-31.6], and 34.3 [95% CI, 19.5-52.4] excess deaths per 1000 person-years, respectively by age category, at an albumin-creatinine ratio of 300 mg/g vs 10 mg/g). In CKD cohorts, adjusted relative hazards of mortality did not decrease with age. In all cohorts, ESRD relative risks and absolute risk differences at lower eGFR or higher albuminuria were comparable across age categories.

Conclusions Both low eGFR and high albuminuria were independently associated with mortality and ESRD regardless of age across a wide range of populations. Mortality showed lower relative risk but higher absolute risk differences at older age.

JAMA. 2012;308(22):2349-2360
 Published online October 30, 2012. doi:10.1001/jama.2012.16817 www.jama.com

Table 1. Baseline Characteristics of Participating General Population and High-Risk Cohorts by Age Group

Source	No. of Participants	Follow-up, y	Age Group, y													
			18-54		55-64		65-74		≥75		18-54		55-64		65-74	
			% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a
General population cohorts																
Alchi ²²	4731	7.4	81	99	2	19	90	3	<0.01	94	0	NA	NA	NA	NA	NA
AKDN ²³	920 686	2.7	66	93	4	16	77	4	10	68	6	8	58	10		
ARIC ^{24,b}	11 441	10.6	6	93	6	55	87	7	40	78	11	<0.01	72	33		
AusDiab ^{25,b}	11 179	9.9	61	94	4	18	81	6	14	72	11	7	63	24		
Beaver Dam CKD ²⁶	4857	11.6	31	91	3	27	82	3	26	74	5	16	63	7		
Beijing ^{27,b}	1659	3.9	34	93	5	30	82	5	32	76	7	4	68	7		
CHS ^{28,b}	2988	8.4	NA	NA	NA	NA	NA	NA	25	80	18	75	72	21		
CIRCS ²⁹	11 871	17.0	51	96	3	36	84	3	14	78	4	NA	NA	NA		
COBRA ^{30,b}	2872	4.1	68	110	6	19	96	14	11	87	14	4	78	23		
ESTHER ³¹	9641	5.0	17	92	9	44	86	11	38	78	14	1	70	20		
Framingham ^{32,b}	2956	10.5	37	99	7	33	88	10	25	77	19	5	67	30		
Gubbio ^{33,b}	1681	10.7	50	88	3	50	81	5	NA	NA	NA	NA	NA	NA		
HUNT ^{34,b}	9659	12.0	30	103	5	20	87	9	30	78	14	21	69	23		
IPHS ³⁵	95 451	14.0	34	96	2	31	85	2	30	78	3	5	70	4		
MESA ^{36,b}	6733	6.2	28	92	5	28	84	8	30	77	11	14	69	18		
MRC ³⁶	12 371	6.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	100	57	7		
NHANES III ^{37,b}	15 663	8.5	65	113	7	13	88	15	13	77	20	10	66	27		
Ohasama ³⁸	1956	10.4	17	94	12	42	85	6	31	79	5	10	69	19		
Okinawa BS ³⁹	9599	16.9	58	84	15	19	69	24	15	62	29	8	55	36		
Okinawa BS ⁴⁰	93 216	6.9	46	87	3	25	74	4	19	67	5	10	68	6		
PREVEND ^{41,b}	8385	9.7	66	95	7	18	81	15	16	73	25	0.01	61	35		
Rencho Bernardo ^{42,b}	1474	10.5	11	88	4	25	81	9	26	73	15	39	64	21		
REGARDS ^{43,b}	27 306	5.1	12	100	10	38	91	12	32	80	18	17	70	22		
Severance ⁴⁴	78 201	10.0	74	93	5	20	82	6	5	75	7	1	66	13		
Taiwan ⁴⁵	515 573	8.1	79	98	1	13	79	4	6	70	6	1	61	7		
ULSAM ^{46,b}	1103	11.8	NA	NA	NA	NA	NA	NA	100	76	16	NA	NA	NA		
Total ^c	1 861 052	5.9 (0.003-20.8)	65 (16)	95 (16)	3	18 (15)	79 (15)	4 (15)	11 (15)	71 (15)	7 (15)	6 (16)	60 (16)	11		
High-risk cohorts																
ADVANCE ^{47,b}	10 595	4.8	0.01	83	24	40	85	32	50	75	29	9	66	33		
AKDN (ACR) ^{23,b,d}	102 639	3.0	44	90	20	24	76	23	19	66	28	12	55	39		
CARE ⁴⁸	4098	4.8	32	86	10	37	75	14	30	67	17	1	59	30		
KEEP ⁴⁹	77 902	4.2	50	98	10	23	81	12	17	72	15	10	61	21		
KP Hawaii ^{50,e}	39 884	2.4	38	94	34	27	78	29	20	68	32	16	58	40		
MRFIT ⁵¹	12 854	24.9	91	88	4	9	80	3	NA	NA	NA	NA	NA	NA		
Pima ^{52,b}	5066	13.8	91	124	17	6	91	46	3	82	53	1	72	53		
ZODIAC ^{53,b}	1095	7.9	13	92	23	21	78	30	34	69	42	31	59	50		
Total ^c	254 133	4.4 (0.003-32.0)	46 (20)	94 (20)	17 (17)	24 (17)	79 (17)	21 (17)	19 (17)	69 (17)	25 (17)	11 (17)	58 (17)	34		

Abbreviation: NA, data not applicable.
^aPercentage of participants with albumin-creatinine ratio ≥30 mg/g, protein-creatinine ratio ≥50 mg/g, or dipstick protein ≥1+.
^bStudies measuring albumin-creatinine ratio.
^cTotal number of participants. Overall mean for percentages. Overall mean with range or SD for continuous variables.
^dAll participants with albumin-creatinine ratio measurements in this study were counted in the larger dipstick data pool and thus are not accounted for in the overall total number of participants.
^eStudies measuring protein-creatinine ratio.

Table 2. Baseline Characteristics of Participating Chronic Kidney Disease Cohorts by Age Group

Source	No. of Participants	Follow-up, y	Age Group, y													
			18-54		55-64		65-74		≥75		18-54		55-64		65-74	
			% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a	% of Total	Mean Albuminuria, eGFR % ^a
AASK ^{54,b}	1094	8.8	48	45	72	33	47	54	20	46	49	NA	NA	NA	NA	NA
BC CKD ⁵⁵	17 426	3.3	15	47	87	17	41	79	28	37	72	40	31	71		
CRIC ^{56,c}	308	6.1	30	24	95	21	23	83	29	22	84	21	20	81		
Geisinger⁵⁷																
Measuring albumin-creatinine ratio ^c	3361	3.5	7	49	62	20	51	44	36	51	41	38	50	42		
Dipstick protein measurement	4509	3.9	7	45	45	14	49	28	28	50	23	50	49	23		
GLOMIS-1⁵⁸																
Measuring albumin-creatinine ratio ^c	537	4.2	5	38	71	14	36	59	34	34	47	47	30	48		
Measuring protein-creatinine ratio ^b	470	4.2	16	32	92	13	31	100	27	30	91	44	27	97		
KPNM ⁵⁹	1627	4.6	6	47	54	14	49	38	36	48	31	44	44	27		
MASTERPLAN ^{60,c}	636	4.1	29	37	94	28	37	84	34	36	79	9	36	84		
MDRD ^{61,b}	1730	14.1	57	43	86	28	38	78	15	38	74	NA	NA	NA		
MMKD ^{62,b}	202	4.0	67	52	95	31	39	95	1	16	100	NA	NA	NA		
NephroTest ^{63,c}	928	2.6	34	49	71	25	42	63	25	40	58	16	33	57		
RENAAL ^{64,c}	1513	2.8	22	44	100	44	41	100	34	39	100	NA	NA	NA		
STENO ^{65,c}	886	8.8	85	86	52	11	77	33	4	65	41	1	73	0		
Sunnybrook ^{66,c}	3385	2.3	13	43	88	16	41	84	26	38	83	44	33	84		
Total ^d	38 612	4.2 (0.003-18.9)	19 (27)	49 (27)	79 (18)	19 (18)	43 (18)	70 (18)	28 (18)	41 (18)	62 (18)	35 (14)	37 (14)	59		

Abbreviation: NA, data not applicable.
^aPercentage of participants with albumin-creatinine ratio ≥30 mg/g, protein-creatinine ratio ≥50 mg/g, or dipstick protein ≥1+.
^bStudies measuring protein-creatinine ratio.
^cStudies measuring albumin-creatinine ratio.
^dTotal number of participants. Overall mean for percentages. Overall mean with range or SD for continuous variables.